Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis

The Lancet

Volumn 391, Issue 10124, 2018, Pages 933-

  Moslehi, Javid J ^a   Salem, Joe Elie ^a,b   Sosman, Jeffrey A ^c   Lebrun Vignes, Bénédicte ^b   Johnson, Douglas B ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b SORBONNE UNIVERSITÉ   (France)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNE CHECKPOINT INHIBITOR; UNCLASSIFIED DRUG;

CANCER IMMUNOTHERAPY; DRUG FATALITY; HUMAN; LETTER; MALIGNANT NEOPLASM; MEDICAL DOCUMENTATION; MYOCARDITIS; PRIORITY JOURNAL;

EID: 85042943560     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(18)30533-6     Document Type: Letter

References (5)

1. Wolchok, JD, PD-1 blockers. Cell, 162, 2015, 937.
2. Johnson, DB, Balko, JM, Compton, ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375 (2016), 1749–1755.
3. Heinzerling, L, Ott, PA, Hodi, FS, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer, 4, 2016, 50.
4. Escudier, M, Cautela, J, Malissen, N, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation 136 (2017), 2085–2087.
5. Lindquist, M, VigiBase, the WHO global ICSR database system: basic facts. Drug Inf J 42 (2008), 409–419.